Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 3/20 | 0.35 |
| ▸ | CA9 | Q16790 | 3/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | MMP1 | P03956 | 1/20 | 0.31 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
| ▸ | MMP3 | P08254 | 1/20 | 0.31 |
| ▸ | MMP8 | P22894 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CES2 | O00748 | 2/20 | 0.31 |
| ▸ | CES1 | P23141 | 2/20 | 0.31 |
| ▸ | DNM1 | Q05193 | 4/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL969638 | 0.80 | CA12 (0.39) | ALDH1A1CA12CA9CA1CA2 | |
| SCHEMBL9506005 | 0.80 | ALDH1A1 (0.33) | ALDH1A1CA12CA9CA1 | |
| SCHEMBL7308189 | 0.78 | CA12 (0.42) | ALDH1A1CA12CA9CA1MMP1 | |
| SCHEMBL7305501 | 0.77 | CA12 (0.48) | ALDH1A1CA12CA9CA1MMP1 | |
| SCHEMBL968054 | 0.77 | CA12 (0.45) | ALDH1A1CA12CA9CA1EPHX2 | |
| SCHEMBL9507679 | 0.76 | CA12 (0.35) | ALDH1A1CA12CA9CA1EPHX2 | |
| SCHEMBL2687823 | 0.76 | ALDH1A1 (0.36) | ALDH1A1 | |
| SCHEMBL9504607 | 0.75 | ALDH1A1 (0.32) | ALDH1A1CA12CA9CA1EPHX2 | |
| SCHEMBL7303961 | 0.74 | ALDH1A1 (0.43) | ALDH1A1CES2CES1 | |
| SCHEMBL9504644 | 0.73 | CA12 (0.36) | ALDH1A1CA12CA9CA1MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1278735-B1 | 2,4-DI(HETERO-)ARYLAMINO(-OXY)-5-SUBSTITUTED PYRIMIDINES AS ANTINEOPLASTIC AGENTS | ASTRAZENECA AB (SE) | 2010-06-30 | — | — | EP | disclosed |
| US-20070225209-A1 | COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL DISORDERS AND DISEASES | MYRIAD GENETICS, INCORPORATED (US) | 2007-09-27 | — | — | US | disclosed |
| EP-1272477-B1 | PYRIMIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2007-05-09 | — | — | EP | disclosed |
| EP-1268444-B1 | 2,4-DI(HETERO-)ARYLAMINO(-OXY)-5-SUBSTITUTED PYRMIDINES AS ANTINEOPLASTIC AGENTS | ASTRAZENECA AB (SE) | 2007-01-17 | — | — | EP | disclosed |
| US-7153964-B2 | Pyrimidine compounds | ASTRAZENECA AB (SE) | 2006-12-26 | — | — | US | disclosed |
| US-7067522-B2 | 2,4,DI (hetero-) arylamino (-oxy)-5-substituted pyrimidines as antineoplastic agents | ASTRAZENECA AB (SE) | 2006-06-27 | — | — | US | disclosed |
| US-20050090515-A1 | 2,4,DI (hetero-) arylamino (-oxy) -5-substituted pyrimidines as antineoplastic agents | ASTRAZENECA AB | 2005-04-28 | — | — | US | disclosed |
| US-6838464-B2 | 2,4-Di(hetero-)arylamino(-oxy)-5-substituted pyrimidines as antineaoplastic agents | ASTRAZENECA AB (SE) | 2005-01-04 | — | — | US | disclosed |
| US-20040226056-A1 | Compositions and methods for treating neurological disorders and diseases | MYRIAD GENETICS, INCORPORATED (US) | 2004-11-11 | — | — | US | disclosed |
| EP-1140860-B1 | PYRIMIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2004-09-22 | — | — | EP | disclosed |
| EP-1286972-A1 | PYRIMIDINE COMPOUNDS | AstraZeneca AB (SE) | 2003-03-05 | — | — | EP | disclosed |
| EP-1278735-A1 | 2,4-DI(HETERO-)ARYLAMINO(-OXY)-5-SUBSTITUTED PYRIMIDINES AS ANTINEOPLASTIC AGENTS | AstraZeneca AB (SE) | 2003-01-29 | — | — | EP | disclosed |
| EP-1272477-A1 | PYRIMIDINE COMPOUNDS | AstraZeneca AB (SE) | 2003-01-08 | — | — | EP | disclosed |
| EP-1268444-A1 | 2,4-DI(HETERO-)ARYLAMINO(-OXY)-5-SUBSTITUTED PYRMIDINES AS ANTINEOPLASTIC AGENTS | AstraZeneca AB (SE) | 2003-01-02 | — | — | EP | disclosed |
| EP-1140860-A1 | PYRIMIDINE COMPOUNDS | AstraZeneca AB (SE) | 2001-10-10 | — | — | EP | disclosed |
| WO-2001064656-A1 | 2,4,DI(HETERO-)ARYLAMINO(-OXY)-5-SUBSTITUTED PYRIMIDINES AS ANTINEOPLASTIC AGENTS | ASTRAZENECA AB (SE) | 2001-09-07 | — | — | WO | disclosed |
| WO-2001064654-A1 | PYRIMIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2001-09-07 | — | — | WO | disclosed |
| WO-2001064653-A1 | PYRIMIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2001-09-07 | — | — | WO | disclosed |
| WO-2001064655-A1 | 2, 4-DI(HETERO-)ARYLAMINO (-OXY)-5-SUBSTITUTED PYRIMIDINES AS ANTINEOPLASTIC AGENTS | ASTRAZENECA AB (SE) | 2001-09-07 | — | — | WO | disclosed |
| WO-2000039101-A1 | PYRIMIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2000-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225209-A1 | COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL DISORDERS AND DISEASES | CLN6, PMP22, PSEN2 | ALDH1A1 1672/4885CA12 712/4885CA9 1655/4885 |
| US-20050090515-A1 | 2,4,DI (hetero-) arylamino (-oxy) -5-substituted pyrimidines as antineoplastic agents | CDK2, CDK4, CCNI | ALDH1A1 1393/4885CA12 4661/4885CA9 3425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.